Latest News

Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer
Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

February 14th 2025

Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.

Data from the CheckMate 7FL trial may inform treatment decisions regarding preoperative immunotherapy for patients with breast cancer.
Neoadjuvant Nivolumab Combo Boosts Pathologic Response in ER+ Breast Cancer

February 13th 2025

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.
Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer

February 12th 2025

Findings from the ICE3 trial revealed that no serious adverse effects were experienced related to the use of cryoablation in ipsilateral breast tumors.
Breast Cryoablation Inhibits Recurrence, Enhances Survival in Breast Cancer

February 11th 2025

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer
Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

February 9th 2025